Table 3. Association between the ERCC1/2 gene polymorphisms and prognosis in 87 NSCLC patients who received definitive radiotherapy.

Gene	MST (months)	95% CI	P	Median PFS (months)	95% CI	P
rs11615
AA	6.77	0–14.05	0.000	5.13	0–15.13	0.019
AG	19.77	11.14–28.40		11.33	5.76–16.91
GG	30.90	12.83–48.97		18.87	12.56–19.58
A allele	16.17	9.10–23.24	0.024	11.33	8.66–14.01	0.005
G allele	30.90	12.83–48.97		18.87	13.96–23.78
rs3212961
GG	24.77	4.75–44.79	0.735	11.53	6.41–16.66	0.910
GT	23.97	15.75–32.19		18.07	12.67–23.47
TT	24.93	9.37–40.49		11.60	5.28–19.92
G allele	24.93	18.95–30.91	0.441	16.17	11.84–20.50	0.897
T allele	24.77	4.75–44.79		11.53	6.41–16.66
rs3212986
AA	71.13	0–160.416	0.092	15.53	0–38.01	0.718
AC	29.10	18.92–39.28		18.70	11.91–25.49
CC	21.53	12.97–30.09		14.67	8.849–20.49
A allele	30.90	15.68–46.12	0.086	18.01	8.85–20.49	0.423
C allele	21.53	12.97–30.09		14.67	11.89–24.25
rs13181
TT	24.93	12.67–36.87	0.692	19.07	9.96–28.19	0.921
TG	24.77	16.19–33.67		16.47	10.17–19.17
rs238406
TT	16.17	0–36.26	0686	11.33	8.92–13.74	0.143
TG	28.67	22.72–34.62		21.50	16.86–26.14
GG	19.80	13.76–25.84		11.30	6.67–15.93
T allele	26.83	21.44–32.22	0.562	16.83	12.16–21.50	0.097
G allele	19.80	13.76–25.84		11.30	6.67–15.93
rs1799793
CC	25.40	18.74–32.05	0.222	15.53	11.79–19.27	0.411
CT	19.07	10.48–27.66		16.13	2.89–29.37

NSCLC, non-small cell lung cancer; CI, confidence interval; MST, median overall survival time; PFS, progression-free survival.